Aclaris Therapeutics (ACRS) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and focus areas

• Focused on developing small molecule oral therapeutics for immunoinflammatory diseases, leveraging a strong drug discovery platform and expertise in St. Louis.

• Lead program ATI-2138 targets ITK and JAK3 for atopic dermatitis, with expansion plans pending early 2025 results.

• Pipeline includes a preclinical selective ITK inhibitor and several discovery programs.

Competitive differentiation and scientific approach

• Emphasizes world-class scientific expertise and a robust translational medicine team.

• Utilizes a large pharma capability within a smaller, agile organization.

• Focuses on targeted, data-driven approaches to drug development.

ATI-2138 mechanism and clinical strategy

• ATI-2138 is an irreversible covalent inhibitor of ITK and JAK3, modulating Th2 T cell activity and cytokine signaling.

• Selectively blocks JAK3 and ITK, aiming for improved safety and efficacy in atopic dermatitis.

• Shifted focus from inflammatory bowel disease to atopic dermatitis for faster clinical catalysts and cost efficiency.

• 12-week open-label trial in moderate to severe atopic dermatitis, with data expected in the first half of 2025.